Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-07-27
2000-05-30
Bernhardt, Emily
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
544369, A61K 31495, C07D41310
Patent
active
06069145&
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to antibiotic compounds, and in particular to antibiotic compounds containing both piperazinone and oxazolidinone rings. This invention further relates to processes for their preparation, to intermediates useful in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them.
The international microbiological community continues to express serious concern that the evolution of antibiotic resistance could result in strains against which currently available antibacterial agents will be ineffective. In general, bacterial pathogens may be classified as either Gram-positive or Gram-negative pathogens. Antibiotic compounds with effective activity against both Gram-positive and Gram-negative pathogens are generally regarded as having a broad spectrum of activity. The compounds of the present invention are regarded primarily as effective against Gram-positive pathogens because of their particularly good activity against such pathogens.
Gram-positive pathogens, for example Staphylococci, Enterococci, Streptococci and mycobacteria, are particularly important because of the development of resistant strains which are both difficult to treat and difficult to eradicate from the hospital environment once established. Examples of such strains are methicillin resistant staphylococcus (MRSA), methicillin resistant coagulase negative staphylococci (MRCNS), penicillin resistant Streptococcus pneumoniae and multiply resistant Enterococcus faecium.
The major clinically effective antibiotic for treatment of such resistant Gram-positive pathogens is vancomycin. Vancomycin is a glycopeptide and is associated with nephrotoxicity and ototoxicity. Furthermore, and most importantly, antibacterial resistance to vancomycin and other glycopeptides is also appearing. This resistance is increasing at a steady rate rendering these agents less and less effective in the treatment of Gram-positive pathogens.
The present inventors have discovered a class of antibiotic compounds containing an oxazolidinone ring which has useful activity against Gram-positive pathogens including MRSA and MRCNS and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used .beta.-lactams.
We have now discovered a narrow range of compounds that is not suggested by the art and which has good activity against a broad range of Gram-positive pathogens including organisms known to be resistant to most commonly used antibiotics. In comparison with compounds described in the art (for example Walter A. Gregory et al in J.Med.Chem. 1990, 33, 2569-2578 and Chung-Ho Park et al in J.Med.Chem. 1992, 35, 1156-1165) the compounds also possess a favourable toxicological profile.
Accordingly, the present invention provides a compound of the formula (I): ##STR1## wherein: R.sup.1 is of the formula --NHR(.dbd.O)(1-4C)alkyl, --NHS(O).sub.n (1-4C)alkyl wherein n is 0, 1 or 2 or R.sup.1 is hydroxy; formula R.sup.6 (CH.sub.2).sub.m -- wherein either m is 1-4 and R.sup.6 is trifluoromethyl, difluoromethyl, fluoromethyl, (1-4C)alkoxy, (1-4C)alkyl S(O).sub.p -- wherein p is 0, 1 or 2, (1-6C)alkanoyloxy, di-(N-(1-4C)alkyl)amino, N-((1-4C)alkyl)(1-4C)alkanoylamino, cyano, carboxy, (1-4C)alkoxycarbonyl, carbamoyl, N-(1-4C)alkylcarbamoyl, di-(N-(1-4C)alkyl)carbamoyl, N-((1-4C)alkyl)(1-4C)alkanesulphonamido, N.sup.1 -((1-4C)alkyl)ureido, N.sup.1 -((1-4C)alkyl)-N.sup.3 -((1-4C)alkyl)ureido, N.sup.1 -((1-4C)alkyl)-di-(N.sup.3 -(1-4C)alkyl)ureido, or of the formula --OC(.dbd.O)NR.sup.7 (R.sup.8) wherein R.sup.7 and R.sup.8 are independently hydrogen or (1-4C)alkyl or of the formula --N(R.sup.9)SO.sub.2 NR.sup.7 (R.sup.8) wherein R.sup.7 and R.sup.8 are as hereinabove defined and R.sup.9 is (1-4C)alkyl; (1-4C)alkylamino, (1-4C)alkanesulphonamido, ureido, N.sup.3 -((1-4C)alkyl)ureido, di-(N.sup.3 -(1-4C)alkyl)ureido or of the formula --NHSO.sub.2 NR.sup.7 (R.sup.8) wherein R.sup.7 and R.sup.8 are as hereinabove defined;
In this
REFERENCES:
patent: 4346102 (1982-08-01), Langlois et al.
patent: 4705799 (1987-11-01), Gregory
patent: 5164510 (1992-11-01), Brickner
patent: 5182403 (1993-01-01), Brickner
patent: 5231188 (1993-07-01), Brickner
patent: 5523403 (1996-06-01), Barbachyn
patent: 5529998 (1996-06-01), Habich et al.
patent: 5652238 (1997-07-01), Brickner et al.
patent: 5792765 (1998-08-01), Riedl
patent: 5827857 (1998-10-01), Riedl
patent: 5861413 (1999-01-01), Habich
"Stereochemistry of Carbon Compounds" by Ernest L.Eliel,pp. 47-54, 1962.
Andes et al., Pharmacodynamic Activity of an Oxazolidinone in an Animal Infection Model, Abstract F233, Abstract of the 36th ICACC, 1996, p. 140.
Ashtekar et al., Oxazolidinones, A New Class of Synthetic Antituberculosis Agent, Diagn. Microbiol. Infect. Dis., 1991, 14(6), pp. 465-471.
Barbachyn et al., Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity., J. Med. Chem., 1996, vol. 39, pp. 680-685.
Barbachyn et al., Synthesis and Antibacterial Activity of New Tropone-Substituted . . . Substitution on In Vivo Activity, Bioorganic & Medical Chemistry Letters, vol. 6, No. 9, 1996, pp. 1009-1014.
Barbachyn et al., Synthesis and Antibacterial Activity of New Tropone-Substituted . . . Tropone Substition Pattern, Bioorganic & Medical Chemistry Letters, vol. 6, No. 9, 1996, pp. 1003-1008.
Barry, In Vitro Evaluation of DuP 105 and DuP 721, Two New Oxazolidinone Antimicrobial Agents, Antimicrobial Agents and Chemotheraphy, Jan. 1988, 32(1), pp. 150-152.
Borthwick et al., 5-(Acetamidomethyl)-3-Aryldihydrofuran-2-Ones, . . . Two New Classes of Antibacterial Agents, Med. Chem. Res., 1996, pp. 22-27.
Brickner et al., Sythesis and Antibacterial Activity of U-100592 . . . Multidrug-Resistant Gram-Positive Bacterial Infections., J. Med. Chem. 1996k vol. 39, 673-679.
Brickner, Oxazolidinone Antibacterial Agents, Current Pharmaceutical Design, 1996, vol. 2, pp. 175-194.
Brumfitt et al., Antibacterial Oxazolidinones In vitro Activity of a New Analogue, E3709, Diagn. Microbiol. Infect. Dis., 1992, vol. 15, pp. 621-625.
Brumfitt et al., In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazoldinones, Journal of Antimicrobial chemotherapy, 1988, 21(6), pp. 711-720.
Brumfitt et al., Variation in response of Gram-positive cocci to the combination of DuP 721 and ciprofloxacin, J. Anticmicrob. Chemother., 1989, 24(3) pp. 465-466.
Buysse et al. Mutation of the AcrAB Antibiotic Efflux Pump in Esherichia coli Confers Susceptibility to Exazolidinone Antibiotics, Abstract C42, Abstract of the 36th ICACC, 1996, p. 41.
Daly et al., Activity and mechanism of action of DuP 105 and DuP 721, new oxaxolidinone compounds, Journal of Antimicrobial Chemotherapy, 1988, 21(6), pp. 721-730.
Denis et al., 5-Aryl-.cndot.,.cndot. Butenolide, A New Class of Antibacterial Derived . . . N-Aryl Oxazolidinone Dup 721, Bioorganic and Medicinal Chemistry Letters, 1994, vol. 4, No. 16, pp. 1925-1930.
Dostert et al., Structural Modifications in Oxazolidinone Series Leading to Type A or B Selective Monoamine Oxidase Inhibitors, Int. Congress Series. Excerpta Medica, 1982, pp. 197-208.
Eliopoulos et al., In Vitro Activities of New Oxazolidinone Antimicrobial Agents against Enterococci, Antimicrobial Agents and Chemotheraphy, Jul. 1996, 40(7), pp. 1745-1747.
Eustice et al., An Automated Pulse Labelling Method for Structure-Activity Relationship Studies with Antibacterial Oxazolidinones, Durgs. Exptl. Clin. Res., 1990, 16(4), pp. 149-155.
Eustice et al., Mechanism of Action of DuP 721: Inhibition of an Early Event during Initiation of Protein Synthesis, Antimicrobial Agents and Chemotheraphy, Aug, 1988, 32(8), pp. 1218-1222.
Eustice et al., The Mechanism of Action of DuP 721, A New Antibacterial Agent: Effects on Micromolecular Synthesis, Biochem. & Biophys. Res. Commun., Feb. 15, 1988, 150(3), pp. 965-971.
Ford et al., In Vivo Activities of U-100592 and U-100766, . . . against Experimental Bacterial Infections, Antimicrobial Agents and Ch
Bernhardt Emily
Zeneca Limited
LandOfFree
Piperazinonephenyloxazolidinone derivatives and their use as ant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazinonephenyloxazolidinone derivatives and their use as ant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazinonephenyloxazolidinone derivatives and their use as ant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1910575